Healthcare resource utilization and economic burden of antifungal management in patients with hematologic malignancy in Japan: a retrospective database study

References

• Otto WR, Green AM. Fungal infections in children with haematologic malignancies and stem cell transplant recipients. Br J Haematol. 2020;189(4):607–624.
   PubMed Web of Science ®Google Scholar
• Alfandari S, Berthon C, Coiteux V. Antifungal stewardship: implementation in a French teaching hospital. Med Mal Infect. 2014;44(4):154–158.
   PubMed Web of Science ®Google Scholar
• Bays DJ, Thompson GR, 3rd. Fungal infections of the stem cell transplant recipient and hematologic malignancy patients. Infect Dis Clin North Am. 2019;33(2):545–566.
   PubMed Web of Science ®Google Scholar
• Böhme A, Atta J, Mousset S, et al. Antifungal management and resource use in patients with acute myeloid leukaemia after chemotherapy—retrospective analysis of changes over 3 yr in a German hospital. Eur J Haematol. 2012;88(1):68–77.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Aversa F, Cook P, et al. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. Eur J Haematol. 2011;87(4):289–301.
   PubMed Web of Science ®Google Scholar
• Fu R, Gundrum J, Sung AH. Health-care utilization and outcomes of patients at high risk of invasive fungal infection. Clinicoecon Outcomes Res. 2018;10:371–387.
   PubMed Web of Science ®Google Scholar
• Ceesay MM, Sadique Z, Harris R, et al. Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UK. J Antimicrob Chemother. 2015;70(4):1175–1181.
   PubMed Web of Science ®Google Scholar
• Racil Z, Weinbergerova B, Kocmanova I, et al. Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: Fungal InfectioN Database (FIND) analysis, 2005–2009. Int J Infect Dis. 2013;17(2):e101–e109.
   PubMed Web of Science ®Google Scholar
• Tsutsumi I, Kunisawa S, Yoshida C, et al. Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study. Int J Clin Oncol. 2019;24(11):1449–1458.
   PubMed Web of Science ®Google Scholar
• Zaragoza R, Pemán J, Salavert M, et al. Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts? Ther Clin Risk Manag. 2008;4(6):1261–1280.
   PubMedGoogle Scholar
• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006. Clin Infect Dis. 2010;50(8):1091–1100.
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Cheng A, Morrissey CO, et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrob Agents Chemother. 2011;55(5):1953–1960.
   PubMed Web of Science ®Google Scholar
• Dodds Ashley E, Drew R, Johnson M, et al. Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. Pharmacotherapy. 2012;32(10):890–901.
   PubMed Web of Science ®Google Scholar
• Menzin J, Meyers JL, Friedman M, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm. 2009;66(19):1711–1717.
   PubMed Web of Science ®Google Scholar
• Drgona L, Khachatryan A, Stephens J, et al. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species. Eur J Clin Microbiol Infect Dis. 2014;33(1):7–21.
   PubMed Web of Science ®Google Scholar
• Cai J, Prehn A, Schlamm H, et al. Impact of invasive fungal infections on mortality, length of hospital stay, and costs in allogeneic hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant. 2014;20(2):S216.
   Google Scholar
• Menzin J, Lang K, Friedman M, et al. Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data. Value Health. 2005;8(2):140–148.
   PubMed Web of Science ®Google Scholar
• Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health. 2002;5(1):26–34.
   PubMed Web of Science ®Google Scholar
• Kim A, Nicolau DP, Kuti JL. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses. 2011;54(5):e301–312–e312.
   Web of Science ®Google Scholar
• Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis. 2000;31(6):1524–1528.
   PubMed Web of Science ®Google Scholar
• Kohno S, Tamura K, Niki Y, et al. Executive summary of Japanese domestic guidelines for management of deep-seated Mycosis 2014. Med Mycol J. 2016;57(4):e117–e163.
   PubMedGoogle Scholar
• Bassetti M, Righi E, Montravers P, et al. What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. J Antimicrob Chemother. 2018;73(suppl_1):i14–i25.
   PubMedGoogle Scholar
• Pound MW, Townsend ML, Dimondi V, et al. Overview of treatment options for invasive fungal infections. Med Mycol. 2011;49(6):1–580.
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR, 3rd, Denning DW, et al. Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):433–442.
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant. 2009;44(8):453–558.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–359.
   PubMed Web of Science ®Google Scholar
• Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant. 2011;46(5):709–718.
   PubMed Web of Science ®Google Scholar
• Kleinberg M. Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective. Med Mycol. 2005;43(s1):289–S294.
   Google Scholar
• Kontoyiannis DP, Yang H, Song J, et al. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis. 2016;16(1):730.
   PubMed Web of Science ®Google Scholar